Analysis of the reasons behind the ban of tilsiparatide/tilpotide

Tirzepatide is a new type of diabetes and weight loss treatment drug, developed by Eli Lilly (Eli Lilly), with the trade name Mounjaro. The drug regulates blood sugar and appetite by simultaneously activating two incretin receptors, GLP-1 and GIP, and shows significant advantages in type 2 diabetes control and weight management. However, recent rumors on the Internet about "tisipatide being banned" have attracted attention. This actually stems from a misunderstanding of regulatory developments and drug safety assessments, rather than a true global ban.

Up to now, major international drug regulatory agencies, including the US FDA and the EU EMA, have not officially "banned" tisiparatide, and it is still on the market and sold normally in many countries. The so-called "banned" is likely to come from the fact that some countries or regions have not been approved for marketing due to policies, clinical data to be improved, or market strategies during the approval and introduction process, or distribution has been suspended due to supply issues for specific batches. In addition, although tilsiparatide has shown great potential in the field of weight loss, its weight loss indication has not yet been officially registered in some countries, resulting in certain medical uses not being allowed.

As for the drug itself, there is indeed a certain risk of side effects, especially gastrointestinal discomfort such as nausea, vomiting, diarrhea, etc. similar to GLP-1 similar drugs, as well as hypoglycemia (mostly seen when combined with insulin or sulfonylureas) and potential pancreatitis risks. The occurrence of thyroid C-cell tumors has been observed in animal experiments, causing concern from some regulatory agencies, especially when using it in patients with a family history of medullary thyroid cancer. However, these risks have not caused the drug to be removed from the shelves globally. Instead, they are clearly stated in the drug instructions in the form of warnings so that doctors can use the drug rationally after assessing the individual risks of the patient.

Reference materials:https://www.drugs.com/tirzepatide.html